CA-DENODO
31.3.2021 09:02:05 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced Denodo Standard , a new data integration solution available on leading cloud marketplaces. The new offering leverages Denodo’s modern data virtualization engine to deliver superior performance and productivity, enabling real-time analytics and data services without replicating the data into another repository. Denodo Standard lowers the barriers to begin data integration by allowing organizations to purchase it directly from their cloud marketplace of choice—AWS, Microsoft Azure, and Google Cloud Platform. Its cloud infrastructure automation and flexible by the hour pricing enables both enterprises as well as small and medium businesses to rapidly deploy it without a large commitment of time and resources.
To begin a free trial of Denodo Standard on AWS, Azure, or Google Cloud click here .
Denodo Standard provides all the capabilities to quickly get data integration projects into production. Featuring an intuitive web user interface with a powerful no-code/low-code data design studio augmented by AI-powered suggestions and the option to choose from over 150 out-of-the-box connectors to various data sources, Denodo Standard delivers data quickly. The solution enables citizen integrators to connect to cloud data warehouses, data lakes, and SaaS applications, and combine the data from these disparate sources into a unified view for consumption by business users via dashboards and reports, or developers via APIs. Denodo’s modern data virtualization connects to data sources directly where the data resides, and provides an efficient way to make the integrated data securely available without the need to collect the data into an additional repository.
Key capabilities of Denodo Standard include:
- High performance data virtualization engine to integrate and deliver data in real time.
- Modern, unified Web UI with SSO (single sign on).
- Integrated Apache-Zeppelin-based data science notebook.
- Wizard-driven visual no-code/low-code design studio with auto-suggestions and autocomplete.
- Zero-code creation of virtual models to expose data from any source to any consumer much faster.
- No-code creation of data APIs: GraphQL, REST, OData with OAuth, SAML and Open API support.
- Rich Cloud Connectivity including: Amazon Redshift, Azure Synapse Analytics, Databricks Delta, Google BigQuery, cloud data stores such as AWS S3, Azure Data Lake Storage, and Google Cloud Storage and SaaS apps like Salesforce, Marketo and Google Analytics.
For organizations that need additional data management features, such as the machine learning data catalog, they can seamlessly upgrade their solution to the Denodo Platform and expand their data integration layer into an advanced logical data fabric.
Forrester VP, Principal Analyst and author of The Forrester Wave™: Enterprise Data Fabric, Q2 2020 , Noel Yuhanna wrote, “Denodo’s data fabric solution integrates key data management components including data integration, data ingestion, data transformation, data governance and security to support new and emerging use cases including Customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI and ML capabilities, and automation also continue to enhance across data fabric components.”
To understand the differences between the Denodo Standard and the Denodo Platform capabilities, click here .
“The goal of Denodo Standard is to enable organizations of all sizes to unlock the value of their data assets faster, and with a lower cost and resource commitment. By leveraging cloud infrastructure automation, usage-based pricing, and free trials in the cloud marketplaces, we have lowered barriers to start using Denodo for data integration,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “We are excited to be able to bring the value of data virtualization to even more companies, especially small and medium-sized businesses, and we expect many of them to expand beyond their initial use quickly to the enterprise logical data fabric capabilities once they have realized the benefits and the rapid ROI Denodo provides.”
Please Tweet : News: @Denodo launches new fast and easy #dataintegration solution in the #cloud - “Denodo Standard”. Available on @awscloud @Azure @GoogleCloudTech. Free 30-day trial - https://www.denodo.com/en/denodo-platform/free-trials . Logical #datafabric #datavirtualization
About Denodo
Denodo is the leader in data virtualization providing agile, high-performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom